Wegovy vs Compounded Semaglutide: Three Supply Chains, One Molecule, ~60x Price Gap

✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

The global semaglutide story is the largest GLP-1 commercial event of the 2020s. Novo Nordisk’s branded products — Wegovy for chronic weight management, Ozempic for type 2 diabetes — reached $24.4 billion in 2024 sales and account for roughly 7% of all US prescription pharmaceutical spending. Demand has consistently outstripped supply. Between March 2022 and February 2025, the US Food and Drug Administration listed semaglutide on its drug shortage register, which created a defined legal pathway for compounding pharmacies under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act to produce semaglutide for individual patients.

That window built an industry. A 2024 KFF analysis estimated that 25–30% of US semaglutide users were receiving compounded rather than branded product, channelled mostly through telehealth platforms at one-fifth to one-quarter the branded price. The legal ground shifted between October 2024 (FDA’s first declaration that the semaglutide shortage was resolved) and May 2025, materially restricting 503A compounding of semaglutide while leaving 503B pathways and research-grade peptide supply unaffected.

Separately, a research-grade peptide supply chain has existed throughout the same period — the same semaglutide molecule produced for laboratory-use markets under HPLC ≥99% purity specifications with CAS-keyed batch documentation. This supply chain serves academic researchers, peptide-science enthusiasts, and bodybuilding-adjacent communities. It is not a finished drug, is not labelled for human use, and is not part of the FDA-regulated medicinal supply chain.

This guide explains all three supply chains, the molecule they share, what the regulatory differences actually mean, and how the price spectrum reaches roughly 60× between the branded extreme and the research-grade extreme.

TL;DR comparison table

What Wegovy specifically is (vs Ozempic)

Wegovy and Ozempic contain the same molecule — semaglutide — but are FDA-approved as different products for different indications at different dose schedules.

• Ozempic (FDA-approved 2017): semaglutide for type 2 diabetes. Maintenance dose 0.5 mg, 1.0 mg, or 2.0 mg subcutaneous weekly.
• Wegovy (FDA-approved June 2021): semaglutide for chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity. Maintenance dose 2.4 mg subcutaneous weekly.
• Rybelsus (FDA-approved 2019): oral semaglutide for type 2 diabetes, 3, 7, or 14 mg daily tablet.

For weight-loss outcomes specifically, the Wegovy 2.4 mg dose is the FDA-approved dose. The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021)¹ randomised 1,961 adults with BMI ≥30 (or ≥27 with comorbidity) to weekly subcutaneous semaglutide 2.4 mg or placebo for 68 weeks, both with lifestyle intervention. The semaglutide group lost a mean of 14.9% of body weight versus 2.4% on placebo. 50% of the semaglutide group lost ≥15% of body weight; 32% lost ≥20%. The placebo group had 4.9% achieve ≥15% loss.

Mechanistically: semaglutide is a GLP-1 receptor agonist. It increases glucose-dependent insulin release, slows gastric emptying, and acts on hypothalamic appetite centres to reduce hunger and increase satiety. The 2.4 mg/week dose produces sustained appetite suppression that is the primary driver of the weight-loss outcome.

The dose escalation schedule (same across supply chains)

Wegovy’s labelled dosing escalation runs over 16 weeks to manage gastrointestinal tolerability:

• Weeks 1–4: 0.25 mg weekly
• Weeks 5–8: 0.5 mg weekly
• Weeks 9–12: 1.0 mg weekly
• Weeks 13–16: 1.7 mg weekly
• Week 17 onward: 2.4 mg weekly (maintenance)

Compounded semaglutide prescriptions typically follow the same escalation schedule, though prescribers may adjust based on patient tolerability. The escalation matters because the most common reasons for discontinuation (nausea, vomiting, diarrhoea) cluster heavily in the first 8 weeks before the body adapts.

The compounded-semaglutide phenomenon (and the 2024–2025 rule change)

Between March 2022 and February 2025, the FDA listed semaglutide injectable on its drug shortage register. Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act permit US compounding pharmacies, under specific conditions, to compound products that are otherwise commercially available when they appear on the shortage list. Combined with the explosion in telehealth GLP-1 prescribing, this enabled the rapid build-out of a $200–$400/month compounded-semaglutide channel that served an estimated 25–30% of US semaglutide users by mid-2024.

In October 2024 the FDA first declared the semaglutide shortage resolved. Litigation and counter-filings followed. By February 2025, the FDA had formally lifted the shortage classification, and by May 2025 the regulatory window for 503A compounding of semaglutide had materially closed. Many telehealth platforms have since transitioned to either branded Wegovy/Ozempic or to alternative GLP-1 molecules (tirzepatide, retatrutide). Some still offer compounded semaglutide through narrower legal pathways. Our companion guide Compounded Semaglutide vs Brand-Name Ozempic covers the legal evolution in detail.

Research-grade semaglutide: what it is, what it isn’t

Independent of the regulated-medicine supply chains above, semaglutide as a synthetic peptide molecule is also produced by lab-supply manufacturers for the research market. The product is the same 31-amino-acid peptide with the same CAS number (910463-68-2), but it is:

• Supplied as lyophilised powder in glass vials, not as a pre-filled injector. The vial must be reconstituted with bacteriostatic water before any use.
• Specified at HPLC ≥99% purity, with mass spectrometry confirmation of molecular weight and Certificate of Analysis available on request per batch.
• Labelled for laboratory research use only. It is not a finished drug, is not regulated as a medicine, and the labelling explicitly disclaims human use.
• Not formulated with the excipients, preservatives, or stability additives present in the finished pharmaceutical products.

The MedsBase semaglutide peptide is part of this research-grade supply chain. It is sold under research labelling and is intended for laboratory research applications. If you are considering it for any other purpose, you should discuss that decision with a clinician who is familiar with both the molecule and the regulatory framework. The molecule is the same; the labelling, formulation, and regulatory pathway are not.

Bioequivalence considered three ways

“Bioequivalent” has a specific FDA regulatory meaning — identical API, same dose, Cmax and AUC within 80–125% of reference in human PK studies — that applies between two finished drugs being compared for substitution in a pharmacy. The relevant comparisons across the three supply chains here are subtly different:

• Wegovy vs Ozempic vs Rybelsus — same molecule, different finished drugs, different FDA-approved indications and doses. These are formally registered products with their own NDAs.
• Wegovy vs USP-grade compounded semaglutide — in principle the molecule is identical at identical doses. Quality control across compounders varies, which is why batch-level COA from the pharmacy matters. The legal pathway permitting compounding changed materially in 2024–2025.
• Wegovy vs research-grade semaglutide peptide — the molecule is the same at the chemical level. The form, formulation, regulatory pathway, and labelled use are different. Research-grade material is not a finished drug and is not regulated as one.

The chemistry is identical across all three. The supply chain, formulation, regulatory framework, and intended use differ.

Manufacturer disclosure: who makes research-grade semaglutide for MedsBase

The semaglutide peptide stocked by MedsBase is manufactured by WHO-GMP-certified lab-supply producers (including Centurion Laboratories Pvt Ltd, Gujarat, the same facility supplying our Cenforce and Vidalista lines). Production specifications: HPLC purity ≥99.0%, mass-spectrometry confirmation of molecular weight (4113.58 Da for semaglutide free acid), and a Certificate of Analysis per batch retained on file. Provide your order ID and the batch number from the vial when contacting MedsBase customer support, and the COA for that batch is emailed within one business day.

Storage: lyophilised semaglutide is stable at room temperature for short periods and at 2–8°C long-term. Once reconstituted with bacteriostatic water, the solution should be refrigerated and used within approximately 30 days. The MedsBase Peptide Healing Stack and other peptide kits bundle BAC water; standalone BAC water is also available as a SKU.

The full price spectrum (per 30-day equivalent dose at 2.4 mg/week)

The 60× spread between branded Wegovy MSRP and research-grade pricing reflects the difference between finished-drug supply chains (with NDA-grade manufacturing, regulatory compliance, distribution, sales-force, and marketing layers) and research-reagent supply chains (raw peptide produced for laboratory markets without any of those layers). The molecule itself is approximately 5% of the finished-drug cost; the remaining 95% is the layers that make it a regulated medicine.

Side effects: identical molecule, identical profile

The semaglutide side-effect profile is intrinsic to the molecule and applies identically across all three supply chains:¹

• Nausea (~44%, mostly weeks 1–8 during escalation; resolves with adaptation)
• Diarrhoea (~30%)
• Constipation (~24%)
• Vomiting (~24%)
• Abdominal pain (~20%)
• Headache (~14%)
• Fatigue (~11%)

The GI side effects are dose-dependent and cluster in the first 8 weeks of escalation. Slowing escalation, taking the dose with a meal, and staying well-hydrated mitigate most cases. Persistent or severe symptoms warrant a clinician review and possible dose hold or step-down.

Contraindications (same across all supply chains)

Who chooses which supply chain?

• Wegovy via insurance with prior authorisation: the path of least friction when employer or government insurance covers it. The branded product is FDA-approved for the weight-management indication, has full clinical-trial backing, and the supply chain is fully regulated. If coverage is in place and the prior auth clears, this is the simplest choice.
• Wegovy MSRP without insurance: rarely the right choice. At $16,188/year cash, the cost-per-percent-weight-loss is unfavourable compared with alternatives. Consider Novo Nordisk’s co-pay-assistance program if you may qualify.
• Compounded semaglutide via legal telehealth pathways: where still available and legally provided. Quality control depends on the specific compounding pharmacy; ask for the COA for the specific batch dispensed to you, and confirm that the prescribing telehealth platform is operating within the current 503A/503B framework.
• Research-grade semaglutide peptide: for laboratory research purposes per the product labelling. The molecule is the same; the formulation, supply chain, and regulatory framework are not. If you are considering it for any other purpose, that decision should be made in conversation with a clinician who understands the molecule, the regulatory framework, and your specific health context.

The single most consequential decision in the entire GLP-1 space is whether to use semaglutide at all — the molecule has a strong safety record at the FDA-approved doses but is not appropriate for everyone, particularly those with the contraindications listed above. The supply-chain decision is downstream of that. Our broader peptides catalogue overview and GLP-1 mechanism comparison (Retatrutide vs Tirzepatide vs Semaglutide) cover the broader landscape.

Ordering research-grade semaglutide peptide from MedsBase

MedsBase semaglutide ships from a dedicated peptide warehouse worldwide, with a $50 USD flat peptide shipping fee that covers the cold-chain handling, padded packaging, and BAC water for reconstitution. Discreet packaging applies (plain envelope, no peptide name on the exterior). Payment is accepted via crypto (USDT, BTC, ETH via Plisio), credit card via a regulated crypto on-ramp (statement descriptor is the on-ramp provider name — a regulated card-payment processor), or SEPA bank transfer where available. See our credit card payment guide for detail. Orders are covered by the MedsBase Reshipment Assurance Policy.

Pricing context: The brand-vs-generic price comparison on this page is one entry in MedsBase’s broader Brand-vs-Generic Medication Pricing Index — a quarterly-updated reference covering 15 brand-vs-generic pairs across ED, GLP-1, hair-loss, PrEP, and cosmetic clusters, with full methodology and citation disclosure.

Frequently Asked Questions

Is research-grade semaglutide the same molecule as Wegovy?

Yes, at the chemical level. All three semaglutide supply chains discussed here (branded Wegovy, US-compounded, research-grade peptide) contain the same 31-amino-acid GLP-1 receptor agonist with CAS number 910463-68-2 and molecular weight 4113.58 Da. The molecule itself does not change between supply chains. What changes is the form (pre-filled injector vs vial vs lyophilised powder), the formulation (with or without excipients and preservatives), the regulatory pathway, and the labelled use. Research-grade material is labelled for laboratory research and is not a finished drug.

Is the MedsBase semaglutide peptide FDA-approved?

No. Research-grade peptides are not FDA-approved drugs. They are produced as research reagents for laboratory use, and the labelling explicitly says so. The semaglutide molecule itself is FDA-approved in three different finished drugs (Wegovy, Ozempic, Rybelsus), each with its own regulatory file, but the research-grade peptide is a separate product category.

Is compounded semaglutide still legal in the US?

The legal landscape changed materially between October 2024 and May 2025 when the FDA declared the semaglutide shortage resolved. Section 503A and 503B compounding of products that are commercially available outside a shortage is restricted to specific circumstances (clinically meaningful differences from the commercial product, individual patient prescription needs). Some telehealth providers continue to offer compounded semaglutide through narrower legal pathways; the answer depends on the specific provider, your specific clinical situation, and the current FDA position. Consult the provider and a clinician.

Why is research-grade semaglutide so much cheaper?

Research-grade peptide is the raw molecule produced as a laboratory reagent, without the finished-drug supply-chain layers (NDA-grade manufacturing controls beyond purity, formulation with stabilising excipients, regulatory submission costs, US distribution and sales-force infrastructure, DTC advertising, PBM rebate absorption). Those layers add roughly 95% of the cost of finished branded GLP-1 medicines. The molecule itself, at HPLC ≥99% purity, costs a small fraction.

Can I expect the same weight loss with research-grade semaglutide as with Wegovy?

The pharmacology of the molecule does not change between supply chains. The STEP 1 trial weight-loss data (~14.9% mean at 68 weeks, 50% achieving ≥15% loss) are intrinsic to the semaglutide molecule at the 2.4 mg/week dose. Whether the outcome is reproduced in any specific individual depends on the dose actually delivered, the lifestyle context, adherence, and individual biology — these factors apply identically across all supply chains. The MedsBase semaglutide peptide is labelled for research use, and any other use should be considered in conversation with a clinician.

How is research-grade semaglutide injected, given it ships as powder?

Research-grade lyophilised peptides are reconstituted with bacteriostatic water (BAC water) before any use. The researcher selects a target concentration based on the experiment, calculates the volume of BAC water required for that concentration, injects the BAC water into the vial, swirls gently to dissolve, and refrigerates the reconstituted solution. Our companion guide peptides catalogue overview covers reconstitution math in detail. Once reconstituted, the solution is stable for approximately 30 days at 2–8°C.

What about tirzepatide and retatrutide — are they alternatives?

Tirzepatide (the molecule in Mounjaro and Zepbound) is a dual GLP-1 + GIP receptor agonist with the SURMOUNT-1 trial showing ~22.5% mean weight loss at the 15 mg/week dose — numerically higher than semaglutide’s 14.9% at 2.4 mg/week. Retatrutide is an investigational triple GLP-1 + GIP + glucagon agonist with even higher weight-loss readouts in phase 2 trials but is not yet approved. See our three-way GLP-1 comparison for the full mechanism and dosing detail.

What are the contraindications I should worry about most?

The boxed warning concerns are medullary thyroid carcinoma and MEN 2 syndrome — personal or family history is a contraindication. Active pancreatitis or gallbladder disease history warrants careful clinician review. Pregnancy is a contraindication; the molecule should be stopped at least 2 months before planned conception. Severe gastroparesis is a contraindication. If you have type 2 diabetes treated with insulin or a sulfonylurea, hypoglycaemia risk requires dose adjustment of those medications under clinician supervision.

Sources

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989–1002 (STEP 1 trial).
2. US Food and Drug Administration. NDA 215256, Wegovy (semaglutide) injection 2.4 mg. Approval letter, 4 June 2021.
3. US Food and Drug Administration. Drug Shortages Database. Semaglutide injection listing history, March 2022 through February 2025.
4. Federal Food, Drug, and Cosmetic Act, sections 503A and 503B (21 U.S.C. §353a, §353b). Drug compounding provisions.
5. Kaiser Family Foundation. The use and cost of medications for weight loss. KFF Health News analysis, 2024.
6. World Health Organization. Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. WHO Technical Report Series 1003, Annex 6, 2017.
7. Centurion Laboratories Pvt Ltd. WHO-GMP certification under the Indian Central Drugs Standard Control Organisation.

Last clinically reviewed: 18 May 2026.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.